文献速递肝病

美国成人代谢功能障碍相关脂肪性肝病及肝纤维化患病率:基于2017-2020年3月与2021年8月-2023年8月国家健康与营养调查的肝脏弹性成像研究

Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023 data.
PubMed 文献 · Hepatology · 2024-12-24

研究基于美国国家健康与营养调查2017-2020年3月及2021年8月-2023年8月数据,对13538名20岁及以上非西班牙裔白人、非西班牙裔黑人、非西班牙裔亚裔及西班牙裔成年人行瞬时弹性成像评估。结果显示:脂肪性肝病患病率28.7%,纤维化11.3%,代谢功能障碍相关脂肪性肝病(MASLD)25.6%;两调查周期之间MASLD患病率由26.8%降至23.6%,纤维化患病率由10.4%升至12.7%,年龄标化脂肪性肝病患病率无显著差异。

要点

  • 美国成人MASLD患病率25.6%,纤维化(肝硬度>8 kPa)患病率11.3%,脂肪性肝病(受控衰减参数>300 dB/m)患病率28.7%。
  • 两调查周期比较:MASLD患病率由26.8%降至23.6%,纤维化患病率由10.4%升至12.7%,年龄标化脂肪性肝病患病率无显著差异。
  • MASLD和纤维化均与糖尿病、较高体重指数、较高腰臀比、血压升高相关,与非西班牙裔黑人种族-族裔呈负相关。

核心结论

  • 美国人群中MASLD和纤维化患病率均高,且与肥胖和糖尿病并存。
  • 作者认为,慢性肝病的早期发现以及针对生活方式和其他可改变危险因素的干预可能减缓疾病向进展期纤维化和肝硬化进展。

研究设计与样本

  • 基于美国国家健康与营养调查2017年至2020年3月及2021年8月至2023年8月两个周期的横断面研究。
  • 纳入13538名20岁及以上非西班牙裔白人、非西班牙裔黑人、非西班牙裔亚裔及西班牙裔男性和女性。
  • 采用瞬时弹性成像评估肝脏硬度(肝纤维化)和受控衰减参数(肝脂肪变)。

主要发现

  • 脂肪性肝病(受控衰减参数>300 dB/m)患病率为28.7%,纤维化(肝硬度>8 kPa)患病率为11.3%,MASLD患病率为25.6%。
  • 两调查周期之间,年龄标化脂肪性肝病患病率无显著差异,MASLD患病率由26.8%降至23.6%,纤维化患病率由10.4%升至12.7%。
  • 多变量校正分析中,MASLD和纤维化均与糖尿病、较高体重指数、较高腰臀比、血压升高相关,与非西班牙裔黑人种族-族裔呈负相关。
  • MASLD还与男性、非西班牙裔亚裔、糖尿病前期、较高总胆固醇、较低高密度脂蛋白胆固醇及较多久坐生活方式相关。
  • 纤维化还与脂肪性肝病、较低总胆固醇及较低教育程度相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Steatotic liver disease (SLD) is a significant public health burden. Previously, we estimated prepandemic SLD prevalence determined by transient elastography-assessed hepatic steatosis and fibrosis in the United States. We now estimate the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and examine associations with lifestyle, socioeconomic, and other factors. APPROACH AND RESULTS: Liver stiffness and controlled attenuation parameters were assessed on 13,538 non-Hispanic White, non-Hispanic Black, non-Hispanic Asian, and Hispanic men and women aged 20 years and over in the National Health and Nutrition Examination Survey 2017 to March 2020 and August 2021 to August 2023. The prevalence of SLD (controlled attenuation parameter >300 dB/m) was 28.7%, fibrosis (liver stiffness >8 kPa) was 11.3%, and MASLD was 25.6%. Between the 2 survey cycles, the age-standardized SLD prevalence was not significantly different, MASLD prevalence decreased (26.8%-23.6%), and fibrosis prevalence increased (10.4%-12.7%). In multivariable-adjusted analysis, both MASLD and fibrosis were associated with diabetes, higher body mass index, higher waist-to-hip ratio, elevated blood pressure, and inversely associated with non-Hispanic Black race-ethnicity. MASLD was also associated with male sex, non-Hispanic Asian race-ethnicity, prediabetes, higher total cholesterol, lower HDL cholesterol, and greater sedentary lifestyle. Fibrosis was also associated with SLD, lower total cholesterol, and less education. CONCLUSIONS: In the US population, MASLD and fibrosis prevalence are high along with obesity and diabetes. Our findings suggest that early detection of chronic liver disease and targeting lifestyle and other modifiable risk factors may slow disease progression toward advanced fibrosis and cirrhosis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Unalp-Arida A, Ruhl CE. Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023 data. Hepatology. 2024. PMID: 39724144. doi:10.1097/HEP.0000000000001211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。